Product Name: Human KIR Antibody (Lirilumab, Research Use)
Catalog Number: NBR-0056
Target Name: KIR
Trade Name: Lirilumab
Antibody Drug Description: Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[It binds to KIR2DL1/2L3.This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: KIR
Synonyms: KIR3DL1; NKB1; CD158E1; NKB1B 2; CD158e1/2
Target Description: Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis.
Ensembl: ENSG00000167633
Uniprot: P43629